Microbix Biosystems (TSX:MBX) Receives Buy Recommendation from eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
(Thomson Reuters ONE) -
Vancouver, British Columbia, July 20, 1011 - Toronto based eResearch has issued
a new research report on Microbix Biosystems (TSX:MBX), giving the company a
speculative buy recommendation with a 12 month target price of $1.15, more than
triple today's price of $0.35.
InvestmentPitch.com has produced a "video news alert" based on the research
report. If this link is not enabled, please visit www.investmentpitch.com and
enter "Microbix" in the search box.
Microbix develops and commercializes biological products and technologies out of
two facilities in the Greater Toronto area. Current products include a variety
of infectious disease antigens, including flu and hepatitis viruses. The company
sells about 40 different products to more than 11 companies globally, including
names such as Pfizer, Seimens, and Abbott.
Management has taken a core virology business and used the proceeds this
business has generated over the years, expected to be $5.8 million in 2011, and
applied them to develop or acquire high-potential, large-market products to
serve a variety of health-science segments. eResearch believes the company is
now at the threshold and about to reap the benefits.
Flu vaccine production, which occurs in specially-prepared, fertilized chicken
eggs, results in significant waste material. The company, with its VIRUSMAX(TM)
product has developed a patented technology that liberates a significant amount
of additional virus from this debris, greatly enhancing the yield of the virus.
This annual global vaccine market is estimated at about $28 billion, with flu
vaccines at $7 billion, which could climb substantially if more countries, such
as China, pursue a policy of inoculating their populations against the flu.
Mibrobix' need for a reliable supply of highly purified water prompted the
company to develop what they call a water solutions product, which it has been
selling since 2007. Microbix produces and sells filtered water-for-injection, in
20 to 200 litre quantities, for customers whose processes require highly
purified water for such uses as production of tissue culture media, purification
reagents, and facility cleaning.
The company is developing several exciting, large market products which should
be commercially ready over the next 18 -24 months, and could put the company on
a high-growth trajectory.
Every year, with more than 5 million patients in the United States having
catheters placed into their bodies for providing dialysis treatment, for
fighting infections with medications that need to be delivered intravenously,
for providing nutrition, or for indications of oncology, the blood often clots
at the opening of the catheter, which prevents them from functioning properly.
This puts the patient in severe jeopardy, with approximately 1.5 million
patients experiencing catheter-related thrombosis, as well as costing the
industry up to $7,000 per patient to replace these catheters. The company's
blood clot-busting drug, KINLYTIC(TM), addresses both the catheter clearance and
other potential markets.
Another large-market opportunity is the company's innovative proprietary
livestock artificial insemination technology, branded LumiSort(TM). LumiSort
allows Microbix to differentiate livestock sperm between Y chromosomes, where
offspring would result in a bull, and X chromosomes, where offspring would
result in a heifer. The company's technology allows for faster and more accurate
sex determination.
With dairy heifers more valuable than dairy bulls, it is obviously desirable to
deliver female offspring, especially if they come from strong milk-producing
cows. The global dairy cattle market for artificial insemination, in OECD
countries alone, is estimated at $1.4 billion, with about 200 million semen
straws sold annually. In dairy farming, about 90% of reproduction is done
through artificial insemination.
Microbix has a lead relationship with a global livestock artificial insemination
firm that sells approximately 7 million straws globally, and has lined up four
other firms which have expressed strong interest in using the LumiSort
technology. The company anticipates this product will become a strong driver of
revenue for the company going forward.
For a more information about Microbix Biosystems, please visit their website at
www.microbix.com, or phone 416-234-1624.
For a copy of the report, contact eResearch at www.eresearch.ca. While on their
site, sign up for their free reports.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan(at)investmentpitch.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via Thomson Reuters ONE
[HUG#1532436]
Unternehmensinformation / Kurzprofil:
Datum: 20.07.2011 - 18:57 Uhr
Sprache: Deutsch
News-ID 56573
Anzahl Zeichen: 5613
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Microbix Biosystems (TSX:MBX) Receives Buy Recommendation from eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
